MovDisordV3, Main, Exploration, bibRecord, 002D58

Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo‐controlled study

Identifieur interne : 002D58 ( Main/Exploration ); précédent : 002D57; suivant : 002D59

Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo‐controlled study

Auteurs : Roberta Zangaglia [Italie] ; Emilia Martignoni [Italie] ; Margaret Glorioso [Italie] ; Maria Ossola [Italie] ; Giulio Riboldazzi [Italie] ; Daniela Calandrella [Italie] ; Gabriele Brunetti [Italie] ; Claudio Pacchetti [Italie]

Source :

Movement Disorders [ 0885-3185 ] ; 2007-07-15.

RBID : ISTEX:5569BE0D4CA04BBD915FB959B89020337E2E0F86

Descripteurs français

Pascal (Inist)
- Constipation, Gastrointestinal, Macrogol, Parkinson maladie, Placebo, Système nerveux pathologie, Traitement, Trouble fonctionnel.

English descriptors

KwdEn :
- Aged, Chi-Square Distribution, Constipation, Constipation (drug therapy), Constipation (etiology), Double-Blind Method, Dysfunction, Female, Gastrointestinal, Humans, Macrogol, Male, Nervous system diseases, Parkinson Disease (complications), Parkinson disease, Parkinson's disease, Placebo, Polyethylene Glycols (therapeutic use), Severity of Illness Index, Surface-Active Agents (therapeutic use), Time Factors, Treatment, constipation, gastrointestinal dysfunction.
MESH :
- chemical , therapeutic use : Polyethylene Glycols, Surface-Active Agents.
- complications : Parkinson Disease.
- drug therapy : Constipation.
- etiology : Constipation.
- Aged, Chi-Square Distribution, Double-Blind Method, Female, Humans, Male, Severity of Illness Index, Time Factors.

Abstract

Chronic constipation is the most frequent symptom of autonomic system involvement in Parkinson's disease (PD). Quite often the symptom is severe and impairs patients' quality of life. The objective of this study is to determine the efficacy and safety of an isosmotic macrogol solution for the treatment of constipation in PD patients, in a double‐blind, placebo‐controlled study. A total of 57 PD patients with constipation were randomly assigned to receive an isosmotic macrogol electrolyte solution (MC‐ES; 29 patients) or placebo (28 patients) for 8 weeks. Treatment efficacy was defined as complete relief of the symptom or a marked improvement of two of the following indicators: stool frequency, straining, stool consistency, use of rectal laxatives as a rescue therapy. The responder rates were significantly higher in the MC‐ES group both at the first (4 weeks; P < 0.0003) and at the final evaluation (8 weeks; P < 0.0012). The frequency of bowel movements (P < 0.002) and stool consistency (P < 0.006) were significantly changed in the MC‐ES group compared to the placebo group. At the final evaluation, a rectal laxative was used by 2 (12.5%) patients on placebo, whereas no use was recorded in the MC‐ES group. Responder rate for straining showed a favorable trend in patients treated with macrogol versus placebo. Unified Parkinson's Disease Rating Scale Part III and Parkinson's Disease Questionnaire (PDQ‐39) did not show any significant modification in either group during the 8‐week treatment period. The results of this placebo‐controlled study show the efficacy of MC‐ES in the treatment of constipation in PD. MC‐ES was well‐tolerated and did not affect the course of PD. © 2006 Movement Disorder Society

Url:

https://api.istex.fr/document/5569BE0D4CA04BBD915FB959B89020337E2E0F86/fulltext/pdf

DOI: 10.1002/mds.21243

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo‐controlled study</title>
<author><name sortKey="Zangaglia, Roberta" sort="Zangaglia, Roberta" uniqKey="Zangaglia R" first="Roberta" last="Zangaglia">Roberta Zangaglia</name>
</author>
<author><name sortKey="Martignoni, Emilia" sort="Martignoni, Emilia" uniqKey="Martignoni E" first="Emilia" last="Martignoni">Emilia Martignoni</name>
</author>
<author><name sortKey="Glorioso, Margaret" sort="Glorioso, Margaret" uniqKey="Glorioso M" first="Margaret" last="Glorioso">Margaret Glorioso</name>
</author>
<author><name sortKey="Ossola, Maria" sort="Ossola, Maria" uniqKey="Ossola M" first="Maria" last="Ossola">Maria Ossola</name>
</author>
<author><name sortKey="Riboldazzi, Giulio" sort="Riboldazzi, Giulio" uniqKey="Riboldazzi G" first="Giulio" last="Riboldazzi">Giulio Riboldazzi</name>
</author>
<author><name sortKey="Calandrella, Daniela" sort="Calandrella, Daniela" uniqKey="Calandrella D" first="Daniela" last="Calandrella">Daniela Calandrella</name>
</author>
<author><name sortKey="Brunetti, Gabriele" sort="Brunetti, Gabriele" uniqKey="Brunetti G" first="Gabriele" last="Brunetti">Gabriele Brunetti</name>
</author>
<author><name sortKey="Pacchetti, Claudio" sort="Pacchetti, Claudio" uniqKey="Pacchetti C" first="Claudio" last="Pacchetti">Claudio Pacchetti</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:5569BE0D4CA04BBD915FB959B89020337E2E0F86</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1002/mds.21243</idno>
<idno type="url">https://api.istex.fr/document/5569BE0D4CA04BBD915FB959B89020337E2E0F86/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000C07</idno>
<idno type="wicri:Area/Istex/Curation">000C07</idno>
<idno type="wicri:Area/Istex/Checkpoint">001866</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Zangaglia R:macrogol:for:the</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:17566120</idno>
<idno type="wicri:Area/PubMed/Corpus">002638</idno>
<idno type="wicri:Area/PubMed/Curation">002638</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002730</idno>
<idno type="wicri:Area/Ncbi/Merge">001D01</idno>
<idno type="wicri:Area/Ncbi/Curation">001D01</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001D01</idno>
<idno type="wicri:Area/Main/Merge">003C80</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:07-0391072</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001624</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001697</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001602</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Zangaglia R:macrogol:for:the</idno>
<idno type="wicri:Area/Main/Merge">004192</idno>
<idno type="wicri:Area/Main/Curation">002D58</idno>
<idno type="wicri:Area/Main/Exploration">002D58</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo‐controlled study</title>
<author><name sortKey="Zangaglia, Roberta" sort="Zangaglia, Roberta" uniqKey="Zangaglia R" first="Roberta" last="Zangaglia">Roberta Zangaglia</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Unit, IRCCS “C. Mondino Institute of Neurology” Foundation, Pavia</wicri:regionArea>
<wicri:noRegion>Pavia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Martignoni, Emilia" sort="Martignoni, Emilia" uniqKey="Martignoni E" first="Emilia" last="Martignoni">Emilia Martignoni</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Unit of Neurorehabilitation and Movement Disorders, IRCCS “S. Maugeri” Foundation, Scientific Institute of Veruno, Novara</wicri:regionArea>
<wicri:noRegion>Novara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medical Science, University “A. Avogadro”, Novara</wicri:regionArea>
<wicri:noRegion>Novara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Glorioso, Margaret" sort="Glorioso, Margaret" uniqKey="Glorioso M" first="Margaret" last="Glorioso">Margaret Glorioso</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Unit, IRCCS “C. Mondino Institute of Neurology” Foundation, Pavia</wicri:regionArea>
<wicri:noRegion>Pavia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ossola, Maria" sort="Ossola, Maria" uniqKey="Ossola M" first="Maria" last="Ossola">Maria Ossola</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Unit, IRCCS “C. Mondino Institute of Neurology” Foundation, Pavia</wicri:regionArea>
<wicri:noRegion>Pavia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Riboldazzi, Giulio" sort="Riboldazzi, Giulio" uniqKey="Riboldazzi G" first="Giulio" last="Riboldazzi">Giulio Riboldazzi</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurology, University of Insubria, Varese</wicri:regionArea>
<wicri:noRegion>Varese</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calandrella, Daniela" sort="Calandrella, Daniela" uniqKey="Calandrella D" first="Daniela" last="Calandrella">Daniela Calandrella</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurology, University of Insubria, Varese</wicri:regionArea>
<wicri:noRegion>Varese</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brunetti, Gabriele" sort="Brunetti, Gabriele" uniqKey="Brunetti G" first="Gabriele" last="Brunetti">Gabriele Brunetti</name>
<affiliation wicri:level="3"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Promefarm srl, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pacchetti, Claudio" sort="Pacchetti, Claudio" uniqKey="Pacchetti C" first="Claudio" last="Pacchetti">Claudio Pacchetti</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Unit, IRCCS “C. Mondino Institute of Neurology” Foundation, Pavia</wicri:regionArea>
<wicri:noRegion>Pavia</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2007-07-15">2007-07-15</date>
<biblScope unit="vol">22</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="1239">1239</biblScope>
<biblScope unit="page" to="1244">1244</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">5569BE0D4CA04BBD915FB959B89020337E2E0F86</idno>
<idno type="DOI">10.1002/mds.21243</idno>
<idno type="ArticleID">MDS21243</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Chi-Square Distribution</term>
<term>Constipation</term>
<term>Constipation (drug therapy)</term>
<term>Constipation (etiology)</term>
<term>Double-Blind Method</term>
<term>Dysfunction</term>
<term>Female</term>
<term>Gastrointestinal</term>
<term>Humans</term>
<term>Macrogol</term>
<term>Male</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Placebo</term>
<term>Polyethylene Glycols (therapeutic use)</term>
<term>Severity of Illness Index</term>
<term>Surface-Active Agents (therapeutic use)</term>
<term>Time Factors</term>
<term>Treatment</term>
<term>constipation</term>
<term>gastrointestinal dysfunction</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Polyethylene Glycols</term>
<term>Surface-Active Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Constipation</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Constipation</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Chi-Square Distribution</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Constipation</term>
<term>Gastrointestinal</term>
<term>Macrogol</term>
<term>Parkinson maladie</term>
<term>Placebo</term>
<term>Système nerveux pathologie</term>
<term>Traitement</term>
<term>Trouble fonctionnel</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Chronic constipation is the most frequent symptom of autonomic system involvement in Parkinson's disease (PD). Quite often the symptom is severe and impairs patients' quality of life. The objective of this study is to determine the efficacy and safety of an isosmotic macrogol solution for the treatment of constipation in PD patients, in a double‐blind, placebo‐controlled study. A total of 57 PD patients with constipation were randomly assigned to receive an isosmotic macrogol electrolyte solution (MC‐ES; 29 patients) or placebo (28 patients) for 8 weeks. Treatment efficacy was defined as complete relief of the symptom or a marked improvement of two of the following indicators: stool frequency, straining, stool consistency, use of rectal laxatives as a rescue therapy. The responder rates were significantly higher in the MC‐ES group both at the first (4 weeks; P < 0.0003) and at the final evaluation (8 weeks; P < 0.0012). The frequency of bowel movements (P < 0.002) and stool consistency (P < 0.006) were significantly changed in the MC‐ES group compared to the placebo group. At the final evaluation, a rectal laxative was used by 2 (12.5%) patients on placebo, whereas no use was recorded in the MC‐ES group. Responder rate for straining showed a favorable trend in patients treated with macrogol versus placebo. Unified Parkinson's Disease Rating Scale Part III and Parkinson's Disease Questionnaire (PDQ‐39) did not show any significant modification in either group during the 8‐week treatment period. The results of this placebo‐controlled study show the efficacy of MC‐ES in the treatment of constipation in PD. MC‐ES was well‐tolerated and did not affect the course of PD. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Italie</li>
</country>
<region><li>Lombardie</li>
</region>
<settlement><li>Milan</li>
</settlement>
</list>
<tree><country name="Italie"><noRegion><name sortKey="Zangaglia, Roberta" sort="Zangaglia, Roberta" uniqKey="Zangaglia R" first="Roberta" last="Zangaglia">Roberta Zangaglia</name>
</noRegion>
<name sortKey="Brunetti, Gabriele" sort="Brunetti, Gabriele" uniqKey="Brunetti G" first="Gabriele" last="Brunetti">Gabriele Brunetti</name>
<name sortKey="Calandrella, Daniela" sort="Calandrella, Daniela" uniqKey="Calandrella D" first="Daniela" last="Calandrella">Daniela Calandrella</name>
<name sortKey="Glorioso, Margaret" sort="Glorioso, Margaret" uniqKey="Glorioso M" first="Margaret" last="Glorioso">Margaret Glorioso</name>
<name sortKey="Martignoni, Emilia" sort="Martignoni, Emilia" uniqKey="Martignoni E" first="Emilia" last="Martignoni">Emilia Martignoni</name>
<name sortKey="Martignoni, Emilia" sort="Martignoni, Emilia" uniqKey="Martignoni E" first="Emilia" last="Martignoni">Emilia Martignoni</name>
<name sortKey="Ossola, Maria" sort="Ossola, Maria" uniqKey="Ossola M" first="Maria" last="Ossola">Maria Ossola</name>
<name sortKey="Pacchetti, Claudio" sort="Pacchetti, Claudio" uniqKey="Pacchetti C" first="Claudio" last="Pacchetti">Claudio Pacchetti</name>
<name sortKey="Riboldazzi, Giulio" sort="Riboldazzi, Giulio" uniqKey="Riboldazzi G" first="Giulio" last="Riboldazzi">Giulio Riboldazzi</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D58 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D58 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:5569BE0D4CA04BBD915FB959B89020337E2E0F86
   |texte=   Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo‐controlled study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo‐controlled study

Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo‐controlled study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.